Stay updated with breaking news from Sisaf Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer Guildford, England – 13 July 2023 – RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I. Officer. The new position reflects the...
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I. Officer. The new position
SiSaf has been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (PRDD) by the US Food and Drug Administration (FDA) for its osteopetrosis treatment, SIS-101-ADO.
SiSaf will develop miRNA to be tested in pancreatic cancer models in the laboratory. miRNAs are involved in the regulation of various physiological and pathological processes. In tumors, aberrant downregulation of given miRNAs may result in pathological overexpression of oncogenes, rendering miRNA replacement a promising therapeutic strategy. Researchers have demonstrated the tumor-inhibitory potential of miR506-3p and miR24-3p in animal models of pancreatic cancer.
GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the...